Abstract: Provided herein are a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.

Abstract: An increase in agent residence time at a tissue site is provided for by the presence of a barrier. The barrier is a separate entity from the agent when introduced to the tissue. A binding member is included in the barrier for coupling the barrier to the surface of the tissue. In one embodiment, agent is introduced to the tissue prior to attachment of the barrier to the tissue. In another embodiment, agent is presented after the barrier is positioned on the tissue surface. A delivery vehicle may be used to administer the agent and barrier to a patient.

Abstract: An apparatus and method is provided for stenting bifurcated vessels. A proximal angled stent is configured for implanting in a side-branch vessel wherein the proximal angled stent has an angulated portion that corresponds to the angle formed by the intersection of the side-branch vessel and the main vessel so that all portions of the side-branch vessel at the bifurcation are covered by the proximal angled stent. A main-vessel stent is provided for implanting in the main vessel, wherein the main-vessel stent has an aperture or stent cell that aligns with the opening to the side-branch vessel to permit unobstructed blood flow between the main vessel and the side-branch vessel. Side-branch and main-vessel catheter assemblies are advanced over a pair of guide wires for delivering, appropriately orienting, and implanting the proximal angled stent and the apertured stent.

Abstract: Embodiments of stents having profiles that improve gripping of the stent on a stent delivery system are provided. Additionally, embodiments of molds for fabricating the stents are provided.

Abstract: A system and method for coating a tubular implantable medical device, such as a stent, using an applicator and a coating composition are provided.

Abstract: A porous prosthesis for delivering a medication to the site of implantation, and a method of making the same, is disclosed.

Abstract: Implantable devices formed of or coated with a material that includes a polymer having a non-fouling acrylate or methacrylate polymer are provided. The implantable device can be used for treating or preventing a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, patent foramen ovale, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.

Abstract: Provided herein is a copolymer that includes a soft block (A) and a hard block (B) comprising a tyrosine di-peptide. The copolymer can be any of AB, ABA or BAB type block copolymers. The soft block can include a PEA polymer. A coating formed of the copolymer may also include a bioactive agent. The implantable device can be implanted in a patient to treat, prevent, or ameliorate a disorder such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, and/or tumor obstruction.

Abstract: A stent is formed by encasing or encapsulating metallic rings in an inner polymeric layer and an outer polymeric layer. At least one polymer link connects adjacent metallic rings. The stent is drug loaded with one or more therapeutic agent or drug, for example, to reduce the likelihood of the development of restenosis in the coronary arteries. The inner and outer polymeric materials can be of the same polymer or different polymer to achieve different results, such as enhancing flexibility and providing a stent that is visible under MRI, computer tomography and x-ray fluoroscopy.

Abstract: An implantable medical device, such as a stent, is disclosed. The device includes a substrate and a polymeric layer including poly(methylmethacrylate) or poly(butylmethacrylate) supported by the substrate. The polymeric layer contains rapamycin. A barrier is over at least a portion of the polymeric layer to reduce the rate of release of rapamycin from the implantable medical device. The polymeric layer can additionally include poly(ethylene co-vinyl acetate).

Abstract: A coating and a method of coating an implantable medical device, such as a stent, is disclosed. The method includes subjecting the coating to a thermal condition which can result in reduction of the rate of release of an active agent from the coating subsequent to the implantation of the device.

Abstract: A method is provided for forming a polymeric coating on a stent. The method can comprise applying a prepolymer or a combination of prepolymers to the stent and initiating polymerization to form a polymeric coating on the stent. The coating material can optionally contain a biologically active agent or combination of agents.

Abstract: The present invention is directed to a medical device having a polymerized base coat layer for the immobilization of an anti-thrombogenic material, such as heparin, thereon. The binding coat layer is comprised of various chemically functional groups which are stable and allow for the immobilization of the anti-thrombogenic material thereto. Methods for immobilizing the anti-thrombogenic material within the base coat layer posited on a surface of the medical device are also provided.

Abstract: An infusion catheter having a distal shaft with an infusion tube extending from a proximal end to a distal end of the distal shaft, and a proximal cannula with an inner dimension and a distal end attached to a proximal end of the distal shaft to define an opening between the inner diameter of the infusion tube and the inner dimension of the proximal cannula. Also, a guidewire tube disposed within the inner dimension and the distal shaft and extending from the proximal end of the proximal cannula to the distal end of the distal shaft. The inner diameter of the infusion tube, the opening, the exterior dimension of the guidewire tube and the inner dimension cooperate and define sufficient cross sectional sizes to allow a treatment agent to be infused between the proximal end of the proximal cannula and the region of interest.

Abstract: A locking component for locking a medical device onto a guide wire. Such medical devices include, for example, an embolic filter assembly used to capture embolic material that may be created and released into a patient's vasculature during a stenting or angioplasty procedure. The embolic filter assembly tracks along the guide wire, and is delivered to a treatment site where it is locked in place and deployed. The locking component enables the filter assembly to lock onto any standard guide wire, and does not require a modified guide wire that has a specially-designed fitting or stop to accomplish the locking function.

Abstract: A single-wire expandable cage for an embolic filtering device includes a single cage wire coupled to an elongated member, such as a guide wire, and adapted to expand from an unexpanded position to an expanded position in a patient's body vessel. The wire includes a first end and a second end which are coupled to the guide wire. A filter element is attached to the single-wire cage. The single-wire cage may be rotatably mounted to the guide wire or may be slidably disposed on the guide wire to allow the composite cage and filter element to be slid over the guide wire in an over-the-wire fashion once the guide wire is delivered to the target location in the patient's vasculature. One embodiment of the single-wire cage utilizes an offset arrangement in which the guide wire remains extended along the wall of the body vessel once the single-wire cage is deployed. Another embodiment of the device centers the guide wire within the body vessel.

Abstract: A coated stent is provided including a coating composed of one or more co-polymers of ethylene with carboxylic acid wherein the carboxylic acid co-monomer content is 5-50 wt %.

Abstract: A deployment control system provides controlled deployment of an embolic protection device which may include a guide wire, an expandable filter attached to the guide wire near its distal end, and a restraining sheath that maintains the expanded filter in a collapsed position. The deployment control system includes a torque control device which allows the physician to torque the guide wire into the patient's anatomy and a mechanism for preventing the guide wire from buckling as the restraining sheath is being retracted to deploy the expandable filter. A recovery control system for recovering the embolic protection device includes an inner catheter which extends within a lumen of an outer recovery sheath in a coaxial arrangement. A distal portion of the inner catheter extends beyond another recovery sheath during advancement of the recovery system into the vasculature. The recovery sheath can be advanced over the inner catheter to collapse the expandable filter.

Abstract: A hybrid stent is formed which exhibits both high flexibility and high radial strength. The expandable hybrid stent for implantation in a body lumen, such as a coronary artery, consists of radially expandable cylindrical rings generally aligned on a common longitudinal axis and interconnected by one or more links. In one embodiment, a dip-coated covered stent is formed by encapsulating cylindrical rings within a polymer material. In other embodiments, at least some of the rings and links are formed of a polymer material which provides longitudinal and flexural flexibility to the stent. These polymer rings and links are alternated with metallic rings and links in various configurations to attain sufficient column strength along with the requisite flexibility in holding open the target site within the body lumen. Alternatively, a laminated, linkless hybrid stent is formed by encapsulating cylindrical rings within a polymer tube.

Abstract: A stent of variable surface area as determined by stent struts. The stent can have a variable surface area per unit length which accommodates a therapeutic agent. A patterned distribution of therapeutic agent can be provided throughout the stent. The stent can have an increased level of therapeutic agent near an end of the stent. A decreased level of therapeutic agent can be provided near an end of one embodiment of a stent. Indentations can be provided at the surface of the stent with therapeutic agent disposed therein. The stent can be cut with struts of variable thickness to provide the variable stent surface area.